We are live on ! Find out more

Schrodinger

SDGR

Market cap $1.55B

20.75 USD

+1.73

9.1%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

21.08

+0.33

1.59%

1 day

9.1%

5 days

4.43%

1 month

17.96%

3 months

42.12%

6 months

63.39%

Year to date

15.41%

1 year

12.41%

5 years

-66.27%

10 years

-27.55%

About: Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.

Employees: 850

Healthcare Health Information Services

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 13.3%

Neutral 86.7%

Negative 0%

Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs

NEW YORK--(BUSINESS WIRE)---- $SDGR #AI--Schrödinger announced the formation of Tectora, a biotech it co-founded with NEA and RA Capital, focused on immunology and inflammation therapies.

Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The live presentation will take place on Monday, September 14, 2026 at 1:05 p.m. E.T. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery wi.

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

Zacks Investment Research

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 12, 2026, the company granted restricted stock units (RSUs) with respect to 3,315 shares of the company's common stock to two newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement t.

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrödinger, Inc. (SDGR) Q2 2026 Earnings Call Transcript

Schrödinger, Inc. (SDGR) Q2 2026 Earnings Call Transcript

Schrödinger, Inc. (SDGR) Q2 2026 Earnings Call Transcript

Schrodinger Q2 Earnings Call Highlights

Schrodinger NASDAQ: SDGR said second-quarter annual contract value growth accelerated as demand broadened across large pharmaceutical customers, biotechnology companies and materials-science customers, while the company launched early access for Bunsen, its agentic AI co-scientist.

Schrodinger Q2 Earnings Call Highlights

Zacks Investment Research

Schrodinger, Inc. (SDGR) Q2 Earnings and Revenues Top Estimates

Schrodinger, Inc. (SDGR) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.6 per share. This compares to a loss of $0.59 per share a year ago.

Schrodinger, Inc. (SDGR) Q2 Earnings and Revenues Top Estimates

Schrödinger Reports Second Quarter 2026 Financial Results

NEW YORK--(BUSINESS WIRE)---- $SDGR #AI--Today Schrödinger announced financial results for the quarter ended June 30, 2026.

Schrödinger Reports Second Quarter 2026 Financial Results

Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery

NEW YORK--(BUSINESS WIRE)-- #AgenticAI--Schrödinger, Inc. announced a strategic agreement with BMS to deploy Bunsen, Schrödinger's agentic AI co-scientist, within its research organization.

Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery

Schrodinger: A Rare AI-Adjacent Disruptor Still Not Priced For It

Schrödinger is challenging the incumbent drug-trial method—physics-simulated molecular design that cuts the cost, time, and animal testing of building and screening thousands of candidates. The current EV is roughly accounted for by the software leg alone - the royalties business and the disruption TAM are barely priced in, if at all. Three drivers - a regulatory push away from animal testing, AI-led consumption growth, and Bunsen - open up asymmetric upside that is not required for the base case.

Schrodinger: A Rare AI-Adjacent Disruptor Still Not Priced For It

See News Rankings

Price charts implemented using Lightweight Charts™